There are a number of health care reform plans on the drawing boards right now, and they all seem to come with mind-numbing sticker shock. The administration’s new plan and Senator Kennedy’s plan are both estimated to cost $1 trillion over 10 years.

Both President Obama’s and Senator Kennedy’s healthcare plans are estimated to cost $1 trillion over 10 years.  I’ll believe it when I see it. When was the last time the government completed any project on budget?

With so many biotech stocks making big moves and pharmaceutical merger activity moving faster than anything else right now, we turned to one of the smartest analysts in the lucrative biotech field to give us his take on what we should be doing…

Talk about a winter of discontent… Over the past seven weeks, we’ve seen quite possibly one of the best examples of stock market fear in history.

Tune into the financial media and you’re guaranteed to hear an “expert” call the stock market’s bottom at least once a day.

After the 2001 anthrax attacks on government and media figures, no one wanted to take chances. In the worst biological attack in U.S. history, five people died and another 17 were infected. But what of future potential victims who don’t have such diligent facilities managers at their places of work and do come in contact with anthrax spores? TFN eNews reader and Hot Stock Confidential member John H. turned me on to a tiny outfit that addresses this deadly aspect of anthrax exposure.

It wasn’t too long ago that a bad bank just meant one with long lines, rude tellers and high fees. But times are changing and the definition today is completely different.

“Yes we can,” as incoming president Barack Obama famously declared in his presidential victory speech. Head down the road to The Capitol and we’ll need to modify that to, “Yes, we might,” as lawmakers in Congress debate an $825 billion economic stimulus package.

Biotech companies are a great investment right now, says Laura Cadden. And support from the Obama administration will ensure this trend continues. Laura picks four small cap biotech firms set to soar.

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) is a biopharmaceutical company that focuses entirely on RNA-based technologies and primarily, on antisense therapies.